Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication
David A. Garber, Guido Silvestri, Ashley P. Barry, Andrew Fedanov, Natalia Kozyr, Harold McClure, David C. Montefiori, Christian P. Larsen, John D. Altman, Silvija I. Staprans, Mark B. Feinberg
David A. Garber, Guido Silvestri, Ashley P. Barry, Andrew Fedanov, Natalia Kozyr, Harold McClure, David C. Montefiori, Christian P. Larsen, John D. Altman, Silvija I. Staprans, Mark B. Feinberg
View: Text | PDF
Article AIDS/HIV

Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication

  • Text
  • PDF
Abstract

In vivo blockade of CD28 and CD40 T cell costimulation pathways during acute simian immunodeficiency virus (SIV) infection of rhesus macaques was performed to assess the relative contributions of CD4+ T cells, CD8+ T cells, and Ab responses in modulating SIV replication and disease progression. Transient administration of CTLA4-Ig and anti–CD40L mAb to SIV-infected rhesus macaques resulted in dramatic inhibition of the generation of both SIV-specific cellular and humoral immune responses. Acute levels of proliferating CD8+ T cells were associated with early control of SIV viremia but did not predict ensuing set point viremia or survival. The level of in vivo CD4+ T cell proliferation during acute SIV infection correlated with concomitant peak levels of SIV plasma viremia, whereas measures of in vivo CD4+ T cell proliferation that extended into chronic infection correlated with lower SIV viral load and increased survival. These results suggest that proliferating CD4+ T cells function both as sources of virus production and as antiviral effectors and that increased levels of CD4+ T cell proliferation during SIV infections reflect antigen-driven antiviral responses rather than a compensatory homeostatic response. These results highlight the interrelated actions of CD4+ and CD8+ T cell responses in vivo that modulate SIV replication and pathogenesis.

Authors

David A. Garber, Guido Silvestri, Ashley P. Barry, Andrew Fedanov, Natalia Kozyr, Harold McClure, David C. Montefiori, Christian P. Larsen, John D. Altman, Silvija I. Staprans, Mark B. Feinberg

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
CS blockade attenuates the generation and in vivo CTL activity of
      ...
CS blockade attenuates the generation and in vivo CTL activity of SIV-specific CD8+ T cell responses. (A) Levels of Gag181–189-specific (CTPYDINQM-specific) CD8+ T cells (red trace), Tat28–35-specific (STPESANL-specific) CD8+ T cells (yellow trace), or the sum of Gag181–189- and Tat28–35-specific CD8+ T cells (blue trace) as percentages of CD8+ T cells in peripheral blood (left axes) and the level of the sum of Gag181–189- and Tat28–35-specific CD8+ T cells as a percentage of CD8+Ki67+ T cells (black trace) in peripheral blood (right axes). Left column, control macaques; right column, CS blockade macaques. Gray bars denote the treatment period. (B) Levels (%) of peripheral blood CD8+ T cells that exhibit the Ki67 antigen, a marker of cellular proliferation, by flow cytometry. Control macaques: ROz5 (black), RBm6 (blue), RVy5 (red), RYt5 (green). CS blockade macaques: REp6 (black), REo6 (blue), RIc6 (red), RCr5 (green). The gray bar denotes the treatment period. (C) Nucleotide sequences of cDNA clones encoding SIV tat exon 1 were determined at the indicated times after infection and were compared to the WT parental SIVmac239 sequence. Frequencies of cDNA clones that exhibited one or more nonsynonymous mutations within the region encoding the Tat28–35 (STPESANL) epitope are shown for individual macaques in the control or CS blockade groups. (D) Correlation of the level of Tat28–35-specific (STPESANL-specific) CD8+ T cells and the frequency of mutation within the Tat28–35 coding region at 20 days following SIV infection. The P value was determined by the Spearman rank correlation test. Control macaques (circles): ROz5 (black), RBm6 (blue), RVy5 (red), RYt5 (green); CS blockade macaques (triangles): REp6 (black), REo6 (blue), RIc6 (red), RCr5 (green).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts